What is tesamorelin?
Tesamorelin is a lab-made version of growth hormone–releasing hormone (GHRH), the signal the brain sends to tell the pituitary gland to release growth hormone. Branded tesamorelin is approved for one narrow use, reducing excess belly fat in adults with HIV-associated lipodystrophy. Compounded tesamorelin is different from an FDA-approved product: it is not FDA-approved.
These articles cover how tesamorelin works, what its clinical trials measured, side effects, and how it compares with other growth-hormone peptides. It is prescription-only: a licensed provider reviews every request, and not everyone qualifies.
25 articles on this topic
-

Tesamorelin for Belly Fat: What the Studies Show
Tesamorelin has reduced visceral abdominal fat in randomized trials, most convincingly in adults with HIV-associated lipodystrophy. That evidence does not make it a general weight-loss drug or a reliable way to shrink the fat just under the skin.
-

Tesamorelin Side Effects: Rates, Risks, Monitoring
The most common tesamorelin side effects are injection-site reactions and joint pain; glucose, IGF-1 and cancer history are the monitoring issues that can change the plan.
-

Tesamorelin vs Sermorelin: What Actually Differs
Both are growth-hormone-releasing hormone analogues and they are not interchangeable: one is a 44-amino-acid molecule with a current US approval, the other a 29-amino-acid fragment whose branded product left the market in 2008.
-

Tesamorelin Dosage: How Prescribers Set It
Tesamorelin is dosed daily in the trials and current brand label, but the milligram amount depends on the formulation. IGF-1, glucose, indication and tolerability matter more than a copied schedule.
-

What Does Tesamorelin Do?
In a 26-week Phase 3 trial in adults with HIV-associated lipodystrophy, visceral fat fell 10.9% on tesamorelin versus 0.6% on placebo; the pooled Phase 3 analysis reported a 15.4% effect against placebo.
Page 2 of 2 · 25 articles